Other studies have suggested that NfL levels are a valuable biomarker of neuroaxonal injury in chemotherapy-induced peripheral neuropathy, which occurs mainly when paclitaxel is used to treat breast and ovarian cancer.21,43,44 We were unable to demonstrate the same correlation in our study. The gene discussed is NEFL; the disease is ovarian carcinoma.